Some of the risks that FDA have been found so far during a three-year study of the Artisan are:

a yearly loss of 1.8% of the endothelial cells,
0.6% risk of retinal detachment,
0.6% risk of cataract (other studies have shown a risk of 0.5–1.0%), and
0.4% risk of corneal swelling.Other risks include:

0.03–0.05% eye infection risk, which in worst case can lead to blindness. (This risk exists in all eye surgery procedures and is not unique to IOLs.) glaucoma,
astigmatism,
remaining near or far sightedness,
rotation of the lens inside the eye one or two days after surgery.One of the causes of the risks above is that the lens can rotate inside the eye if the PIOL is too short, if the eye was incorrectly measured, or because the sulcus has a slightly oval shape (the height is slightly smaller than the width). Toric IOLs must be powered and aligned inside the eye on a meridian that corrects the patients preexisting astigmatism. Again, these lenses can rotate inside the eye postoperatively or be placed incorrectly by the operating surgeon. Either way, the patients preexisting astigmatism may not be corrected completely or may even increase. When standard IOLs are implanted with a CLEAR procedure, in substitution of the patients crystalline, astigmatism is typically not corrected, as astigmatism is mainly attributable to a deformation of the cornea. Toric IOLs may be used during the CLEAR procedure to correct astigmatism. The surgeon can ascertain the astigmatic, or steepest, meridian in a number of ways, including manifest refraction or corneal topography.
They are notorious for their negative impact on the corneal endothelial lining, which is vital for maintaining a healthy clear cornea. Iris-fixated PIOLs, attached by claws to the mid-peripheral iris by a technique called enclavation. It is believed to have a lesser effect on corneal endothelium. The main complication with this type is their tendency to cause endothelial cell reduction. Sulcus-supported PIOLs, placed in the posterior chamber in front of the natural crystalline lens. This type of PIOLs is gaining more and more popularity. They have special vaulting so as not to be in contact with the normal lens. The main complication with older versions was a small possibility of cataract formation. Blue-light filtering IOLs
Blue light filtering IOLs filter the UV and high-energy blue light present in natural and artificial light, both of which can cause vision problems; however too much filtering of blue light can increase depression, especially in the winter months (SAD). The trademarked "Natural Yellow" material is available in three hydrophilic IOLs. Dr. Patrick H. Benz of Benz Research and Development created the first IOL material to incorporate the same UV-A blocking and violet light filtering chromophore thats present in the human crystalline lens in order to attempt to protect the retina after cataract extraction of the natural crystalline lens. A Cochrane Review found little evidence of important differences between blue‐light filtering and non‐blue‐light filtering lenses for protecting the macula (back of the eye) after cataract surgery. This was due to studies being too small and too short‐term to provide reliable results.